Gerne leiten wir Informationen und die Einschätzung der European Business Association zu klinischen Studien in der Ukraine weiter:
(…)There is a big problem with the restoration of Clinical Trials in Ukraine. It is very important to communicate to global R&D companies that Ukraine continues to conduct CT, all processes are adapted, all stakeholders are working and ready for further development of CT in Ukraine.
With the participation of the experts of the CT Subcommittee EBA, an open information letter was prepared, based on the official data of the regulator, surveys, received communication from state institutions.
Weitere Informationen können Sie dem offenen Brief der EBA entnehmen: Open letter 446 CTS EBA 02.06.23_Eng_FS
